Literature DB >> 19852956

Activated Rac1 requires gp130 for Stat3 activation, cell proliferation and migration.

Rozanne Arulanandam1, Mulu Geletu, Hélène Feracci, Leda Raptis.   

Abstract

Rac1 (Rac) is a member of the Rho family of small GTPases which controls cell migration by regulating the organization of actin filaments. Previous results suggested that mutationally activated forms of the Rho GTPases can activate the Signal Transducer and Activator of Transcription-3 (Stat3), but the exact mechanism is a matter of controversy. We recently demonstrated that Stat3 activity of cultured cells increases dramatically following E-cadherin engagement. To better understand this pathway, we now compared Stat3 activity levels in mouse HC11 cells before and after expression of the mutationally activated Rac1 (Rac(V12)), at different cell densities. The results revealed for the first time a dramatic increase in protein levels and activity of both the endogenous Rac and Rac(V12) with cell density, which was due to inhibition of proteasomal degradation. In addition, Rac(V12)-expressing cells had higher Stat3, tyrosine-705 phosphorylation and activity levels at all densities, indicating that Rac(V12) is able to activate Stat3. Further examination of the mechanism of Stat3 activation showed that Rac(V12) expression caused a surge in mRNA of Interleukin-6 (IL6) family cytokines, known potent Stat3 activators. Knockdown of gp130, the common subunit of this family reduced Stat3 activity, indicating that these cytokines may be responsible for the Stat3 activation by Rac(V12). The upregulation of IL6 family cytokines was required for cell migration and proliferation induced by Rac(V12), as shown by gp130 knockdown experiments, thus demonstrating that the gp130/Stat3 axis represents an essential effector of activated Rac for the regulation of key cellular functions. 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19852956     DOI: 10.1016/j.yexcr.2009.10.017

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  16 in total

1.  Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.

Authors:  Peng-Chieh Chen; Hiroko Wakimoto; David Conner; Toshiyuki Araki; Tao Yuan; Amy Roberts; Christine E Seidman; Roderick Bronson; Benjamin G Neel; Jonathan G Seidman; Raju Kucherlapati
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

Review 2.  The R(h)oads to Stat3: Stat3 activation by the Rho GTPases.

Authors:  Leda Raptis; Rozanne Arulanandam; Mulu Geletu; James Turkson
Journal:  Exp Cell Res       Date:  2011-05-18       Impact factor: 3.905

3.  A membrane penetrating peptide aptamer inhibits STAT3 function and suppresses the growth of STAT3 addicted tumor cells.

Authors:  Corina Borghouts; Natalia Delis; Boris Brill; Astrid Weiss; Laura Mack; Peter Lucks; Bernd Groner
Journal:  JAKSTAT       Date:  2012-01-01

4.  Targeting of Rac GTPases blocks the spread of intact human breast cancer.

Authors:  Elad Katz; Andrew H Sims; Duncan Sproul; Helen Caldwell; Michael J Dixon; Richard R Meehan; David J Harrison
Journal:  Oncotarget       Date:  2012-06

5.  Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation.

Authors:  Kenneth Leslie; Sizhi P Gao; Marjan Berishaj; Katrina Podsypanina; Hao Ho; Lionel Ivashkiv; Jacqueline Bromberg
Journal:  Breast Cancer Res       Date:  2010-10-07       Impact factor: 6.466

6.  An anti-cancer WxxxE-containing azurin polypeptide inhibits Rac1-dependent STAT3 and ERK/GSK-3β signaling in breast cancer cells.

Authors:  Zhe Zhang; Zhiyong Luo; Wenpu Min; Lin Zhang; Yaqun Wu; Xiaopeng Hu
Journal:  Oncotarget       Date:  2017-06-27

Review 7.  Endosomes as Signaling Platforms for IL-6 Family Cytokine Receptors.

Authors:  Dirk Schmidt-Arras; Stefan Rose-John
Journal:  Front Cell Dev Biol       Date:  2021-06-01

8.  Genetic Interactions of STAT3 and Anticancer Drug Development.

Authors:  Bingliang Fang
Journal:  Cancers (Basel)       Date:  2014-03-06       Impact factor: 6.639

9.  Effects of syndecan-1 on the expression of syntenin and the migration of U251 glioma cells.

Authors:  Jun Chen; Jun Tang; Wei Chen; Yang Gao; Yang He; Qiang Zhang; Qishan Ran; Fang Cao; Shengtao Yao
Journal:  Oncol Lett       Date:  2017-10-11       Impact factor: 2.967

10.  Tumor cell resistance against targeted therapeutics: the density of cultured glioma tumor cells enhances Stat3 activity and offers protection against the tyrosine kinase inhibitor canertinib.

Authors:  V von Manstein; B Groner
Journal:  Medchemcomm       Date:  2016-10-14       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.